DPP-4 inhibitors × glycemic control

TrialJournal of diabetes and its complications

Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes.

Vivian Fonseca et al.PubMed ↗Publisher ↗

What the trial testedas reported · 313 people

No range given

Reported lower glycemic control, no range given

−0.80percentage points

As reported

difference −0.8 %, no interval

One number in the abstract

the abstract, start to end

from baseline in HbA1c were -1.6% and -0.8% for the sitagliptin and

← favours treatmentfavours comparator →
could be chance
No interval given · direction only, strength unknown
Glycemic control
−0.8
DPP-4 inhibitorsGlycemic control

DPP-4 inhibitors × glycemic controlhelps?replicated

unlikelylikely
0.820.82 without it
← favours treatmentfavours comparator →
this papermore certainless certain
1 / 5

20 papers cite it

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
pooled ittrialcites it

The trial

Full record →Abstract, authors, funding and every citing paper · PMID 23116881